CeNeRx to initiate Phase II depression trial
This milestone is based on the positive results of the Tyrima Phase I program reported earlier in 2008 and the recent completion of Pet brain imaging studies showing
AstraZeneca and Sino Biopharmaceutical’s subsidiary Chia Tai Tianqing Pharmaceutical Group (CTTQ) have signed an exclusive licence agreement for TQC3721.